<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157480</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A00231-46</org_study_id>
    <nct_id>NCT02157480</nct_id>
  </id_info>
  <brief_title>Effect of Electrostimulation on Glucose Profile of Patients With Type 2 Diabetes</brief_title>
  <acronym>ELECTRODIAB2</acronym>
  <official_title>ELECTRODIAB2: Effect of an Outpatient Program of Bi-quadricipital Electrostimulation on Glucose Profile of Sedentary Patients With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amiens University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital Roubaix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevalence of type 2 diabetes (T2D) is increasing worldwide. Lifestyle remains the&#xD;
      cornerstone treatment for patients with T2D who are often overweight and sedentary.&#xD;
&#xD;
      Physical activity improves glucose metabolism of patients with T2D : increased glucose&#xD;
      utilization during acute muscle activity and improved insulin sensitivity after regular&#xD;
      training. The molecular mechanism underlying the effects of exercise on glucose metabolism&#xD;
      involves the glucose transporter GLUT-4 which is regulated by physical activity.&#xD;
&#xD;
      Several studies and meta-analysis have showed that physical activity reduces HbA1c by 0.6% on&#xD;
      average. In addition, other data suggest a decrease in cardiovascular morbidity and mortality&#xD;
      through physical activity.&#xD;
&#xD;
      Recent recommendations for T2D management call for the practice of a structured type of&#xD;
      endurance 150 minutes per week and muscle building 2 times per week. However, implementation&#xD;
      of these recommendations is low, even when integrated into a therapeutic education program.&#xD;
      Adherence is often transient and / or partial. In addition, many T2D subjects are unable to&#xD;
      initiate a physical activity because of disabling complications or comorbidities or because&#xD;
      of a major cardiorespiratory deconditioning.&#xD;
&#xD;
      Neuro-myo electrical stimulation (NMES) is a physical treatment routinely used in functional&#xD;
      rehabilitation to improve muscle strength and volume. The metabolic effect of NMES has been&#xD;
      little studied. A pilot study conducted by our team on a population of 18 subjects with T2D&#xD;
      showed that a week of daily NMES sessions significantly improved insulin sensitivity of about&#xD;
      25% and up to 50 % for good responders. This result contrasted with the low induced energy&#xD;
      expenditure by each 20-minute session of bi-quadricipital NMES, suggesting the possibility of&#xD;
      a humoral or neural mechanism associated with NMES.&#xD;
&#xD;
      To complete this work, we plan a randomized cross-over trial with 3 periods (6 weeks without&#xD;
      NMES (control), 6 weeks with 3 sessions of NMES per week and 6 weeks with 5 sessions of NMES&#xD;
      per week) to assess the glucose profile of sedentary T2D subjects during these different&#xD;
      periods. We hypothesize that the bi-quadricipital NMES could improve glycemic control in T2D&#xD;
      subjects and thus represent an alternative to traditional physical activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean CGM glucose from a 6-day CGM recording</measure>
    <time_frame>week 0, 6, 13, 20</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>week 0, 6, 13, 20</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>fasting plasma glucose</measure>
    <time_frame>Week 0, 6, 13, 20</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>fasting plasma insulin</measure>
    <time_frame>Week 0, 6, 13, 20</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>FFA (free fatty acid)</measure>
    <time_frame>Week 0, 6, 13, 20</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>IL6 (interleukin 6)</measure>
    <time_frame>Week 0, 6, 13, 20</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>TNFalpha</measure>
    <time_frame>Week 0, 6, 13, 20</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>adiponectin</measure>
    <time_frame>Week 0, 6, 13, 20</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CRPus (C Reactive Protein ultra sensitive)</measure>
    <time_frame>Week 0, 6, 13, 20</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>irisin</measure>
    <time_frame>Week 0, 6, 13, 20</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>satisfaction questionnaire</measure>
    <time_frame>Week 0, 6, 13, 20</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>motivation questionnaire for physical activity</measure>
    <time_frame>Week 0, 6, 13, 20</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>cardiometabolic stress test</measure>
    <time_frame>Week 6, 20</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Physical Activity</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual follow-up for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>electrostimulation 3 days per week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 minutes ambulatory bi-quadricipital electrostimulation sessions three times per week for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>electrostimulation 5 days per week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 minutes ambulatory bi-quadricipital electrostimulation sessions five times per week for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .</intervention_name>
    <description>outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)</description>
    <arm_group_label>electrostimulation 3 days per week</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week</intervention_name>
    <description>outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)</description>
    <arm_group_label>electrostimulation 5 days per week</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes treated with lifestyle, oral hypoglycemic agents and/or GLP-1&#xD;
             agonists.&#xD;
&#xD;
          -  HbA1c : 7 to 10%&#xD;
&#xD;
          -  low physical activity (Ricci and Gagnon score below 27)&#xD;
&#xD;
          -  Insulin-resistance (at least one criteria out three):&#xD;
&#xD;
          -  Waist circumference &gt; 80cm in women and &gt; 94cm in men&#xD;
&#xD;
          -  Triglycerides &gt; 150 mg/dl&#xD;
&#xD;
          -  HDL-c &lt; 50 mg/dl for women, &lt; 40 mg/dl for men&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  type 1 diabetes&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  intense usual physical activity&#xD;
&#xD;
          -  pace maker&#xD;
&#xD;
          -  seizure&#xD;
&#xD;
          -  knee or neuromuscular pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne FOURMY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael JOUBERT, MD</last_name>
    <phone>+33231064575</phone>
    <email>joubert-m@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel DESAILLOUD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center University Hospital Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie BRUCATO, PhD</last_name>
      <phone>+33231065227</phone>
      <email>brucato-s@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FONTAINE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital Roubaix</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine FERMON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaetan prevost, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucose profile</keyword>
  <keyword>continuous glucose monitoring</keyword>
  <keyword>electrostimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

